TransMedics Group (NASDAQ:TMDX) PT Raised to $117.00

TransMedics Group (NASDAQ:TMDX) had its target price boosted by Canaccord Genuity Group from $102.00 to $117.00 in a research note published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also recently issued reports on TMDX. Oppenheimer lifted their price objective on TransMedics Group from $105.00 to $125.00 and gave the company an outperform rating in a research report on Wednesday. Piper Sandler reaffirmed an overweight rating and issued a $120.00 price objective (up previously from $95.00) on shares of TransMedics Group in a research note on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an overweight rating in a report on Wednesday. Finally, Morgan Stanley raised their target price on TransMedics Group from $75.00 to $95.00 and gave the company an equal weight rating in a report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $119.00.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $127.99 on Wednesday. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $129.66. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The stock has a market cap of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. The business has a fifty day simple moving average of $85.54 and a 200-day simple moving average of $77.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The business’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period last year, the company posted ($0.08) EPS. On average, sell-side analysts anticipate that TransMedics Group will post 0.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Waleed H. Hassanein sold 56,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $115.63, for a total value of $6,475,280.00. Following the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $8,566,679.81. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 736 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total value of $66,306.24. Following the sale, the insider now directly owns 14,375 shares in the company, valued at approximately $1,295,043.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Waleed H. Hassanein sold 56,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total transaction of $6,475,280.00. Following the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $8,566,679.81. The disclosure for this sale can be found here. Insiders sold a total of 236,378 shares of company stock valued at $23,633,449 in the last quarter. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Venturi Wealth Management LLC bought a new position in shares of TransMedics Group during the first quarter valued at $30,000. Fidelis Capital Partners LLC acquired a new position in shares of TransMedics Group in the 1st quarter worth approximately $35,000. Cutler Group LLC CA grew its position in TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after acquiring an additional 600 shares during the last quarter. RiverPark Advisors LLC acquired a new stake in TransMedics Group during the 3rd quarter valued at $60,000. Finally, First Horizon Advisors Inc. grew its holdings in shares of TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.